Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study
Journal of the Endocrine Society · 02.11.2026 · 10 (12)
DOI: 10.1210/jendso/bvag248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 07.11.2026. Verfasst von Brandon M Podyma und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
Abstract (Originalsprache)
Context
Lipodystrophy syndromes are rare disorders of abnormal fat distribution and metabolic disease. The only approved therapy for generalized lipodystrophy is recombinant leptin (metreleptin), which is not approved for partial lipodystrophy. Recent data suggest efficacy of glucagon-like peptide-1 receptor agonists and glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide (GIP) dual agonists (collectively referred to as incretins) to treat complications of lipodystrophy.
Objective
To compare metabolic outcomes of incretin therapies vs metreleptin in partial lipodystrophy.
Design
Retrospective review of patients who received metreleptin as part of a clinical trial and incretins during routine care under a natural history study.
Setting
NIH Clinical Center. Patients Twelve female patients with partial lipodystrophy, aged 16-85 years. All but 1 patient had diabetes.
Intervention
Eleven patients with partial lipodystrophy were treated with metreleptin (mean duration 104 ± 38 months) before switching to incretin therapy (duration 32 ± 13 months). A twelfth patient took metreleptin and an incretin concurrently. Main outcome measures Outcome measures included hemoglobin A1c, insulin dose, Matsuda index, insulinogenic index, disposition index, fasting glucose and insulin, homeostatic model of beta cell function (HOMA-B), homeostatic model assessment of insulin resistance (HOMA-IR), weight, lipids, liver elastography, and liver steatosis.
Results
Hemoglobin A1c was significantly lower during incretin vs metreleptin treatment (mean difference −1.1 ± 0.4%, range −4.75% to −0.1%, P = .005), associated with modest weight reduction (mean difference −1.5 ± 3.9 kg, range −10.4 to 3 kg, P = .046). Most other metabolic parameters did not differ significantly between treatment periods.
Conclusion
In patients with partial lipodystrophy, incretins may provide better diabetes control than metreleptin, with comparable control of other metabolic parameters.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Brandon M Podyma, Rebecca J Brown
Förderung
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
Zitieren
APA
Podyma, B. M., Lightbourne, M., & Brown, R. J. (2026). Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study. Journal of the Endocrine Society, 10(12). https://doi.org/10.1210/jendso/bvag248
Vancouver
Podyma BM, Lightbourne M, Brown RJ. Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study. Journal of the Endocrine Society. 2026;10(12). doi:10.1210/jendso/bvag248
BibTeX
@article{Podyma2026,
author = {Podyma, Brandon M and Lightbourne, Marissa and Brown, Rebecca J},
title = {Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {12},
doi = {10.1210/jendso/bvag248}
}
EUVIMED